Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia.

Trial Profile

Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Pomaglumetad methionil (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 11 Jun 2012 Primary endpoints added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top